BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23946646)

  • 1. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
    Rezende VM; Rivellis A; Novaes MM; de Alencar Fisher Chamone D; Bendit I
    Drug Des Devel Ther; 2013; 7():699-710. PubMed ID: 23946646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
    Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
    Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
    Titier K; Picard S; Ducint D; Teilhet E; Moore N; Berthaud P; Mahon FX; Molimard M
    Ther Drug Monit; 2005 Oct; 27(5):634-40. PubMed ID: 16175138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
    Pirro E; De Francia S; De Martino F; Fava C; Ulisciani S; Cambrin GR; Racca S; Saglio G; Di Carlo F
    J Chromatogr Sci; 2011; 49(10):753-7. PubMed ID: 22080802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
    Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
    Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
    Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
    Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma.
    Zhang Y; Qiang S; Yu Z; Zhang W; Xu Z; Yang L; Wen A; Hang T
    J Chromatogr Sci; 2014 Apr; 52(4):344-50. PubMed ID: 23574742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
    De Francia S; D'Avolio A; De Martino F; Pirro E; Baietto L; Siccardi M; Simiele M; Racca S; Saglio G; Di Carlo F; Di Perri G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jun; 877(18-19):1721-6. PubMed ID: 19428316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
    Turjap M; Juřica J; Demlová R
    Klin Onkol; 2015; 28(2):105-11. PubMed ID: 25882020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
    Kralj E; Trontelj J; Pajič T; Kristl A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.
    Miura M; Takahashi N; Sawada K
    J Chromatogr Sci; 2011 May; 49(5):412-5. PubMed ID: 21549035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
    Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P
    Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.
    Jourdil JF; Tonini J; Stanke-Labesque F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar; 919-920():1-9. PubMed ID: 23384531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of an high performance liquid chromatography-tandem mass spectrometry method for the determination of imatinib in rat tissues.
    Bianchi F; Caffarri E; Cavalli S; Lagrasta C; Musci M; Quaini F; Savi M
    J Pharm Biomed Anal; 2013 Jan; 73():103-7. PubMed ID: 22709608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study.
    Bende G; Kollipara S; Movva S; Moorthy G; Saha R
    J Chromatogr Sci; 2010; 48(5):334-41. PubMed ID: 20515524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
    Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
    Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
    Parise RA; Ramanathan RK; Hayes MJ; Egorin MJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):39-44. PubMed ID: 12798163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.